Frovatriptan: A Review of Pharmacology, Pharmacokinetics and Clinical Potential in the Treatment of Menstrual Migraine

References

• BrandesJSmithTPowersCLong-term safety, tolerability and efficacy of naratriptan 1mg BID in the prophylactic treatment of menstrually associated migraine [abstract]Headache200242451
   Google Scholar
• BrandesJSavaniNKwongJWPatient satisfaction with oral naratriptan for intermittent prophylaxis of menstrually associated migraine: results form a double-blind, placebo-controlled, parallel group study [abstract]Cephalagia200323705
   Web of Science ®Google Scholar
• BrandesJSavaniNAldertonCNaratriptan vs. placebo for intermittent prophylaxis for menstrually associated migraine (MAM): analysis of migraine-free days [abstract]Cephalagia200323705
   Web of Science ®Google Scholar
• BrownAMHoMThomasDRFunctional effects of frovatriptan (VML 251), sumatriptan and naratriptan on human recombinant 5-HT1 and 5-HT7 receptors [abstract]Headache199838376
   Google Scholar
• BuchanPThe pharmacokinetics of frovatriptan (VML 251/SB 209509), a potent selective 5-HT1B/1D agonist, following single dose administration by oral and intravenous routes to healthy male and female volunteersFunc Neurol199813177
   Google Scholar
• BuchanPKeywoodCWardCPharmacokinetics of frovatriptan (VML 251/SB 209509) in healthy young and elderly male and female subjects [poster]199812th Migraine Trust International Symposium1–4 Sept 1998London, UK
   Google Scholar
• BuchanPWardCOliverSDLack of clinically significant interactions between frovatriptan and ergotamine [abstract]Cephalagia199919364
   Web of Science ®Google Scholar
• BuchanPWardCZeigSFrovatriptan pharmacokinetics are unaffected during a migraine attack [abstract]Cephalagia199919365
   Web of Science ®Google Scholar
• BuchanPGay-FeutryCIn vitro metabolism of frovatriptan [poster]Eur J Neurol20007S38110809919
   PubMed Web of Science ®Google Scholar
• BuchanPKeywoodCWadeAClinical pharmacokinetics of frovatriptanHeadache200242Suppl 2S546212028321
   PubMed Web of Science ®Google Scholar
• CohenAFPostJSacksSPharmacokinetics of frovatriptan in patients with renal impairment [abstract]Cephalagia199919365
   Web of Science ®Google Scholar
• ComerMBPharmacology of the selective 5-HT1B/1D agonist frovatriptanHeadache200242Supp 24753
   Web of Science ®Google Scholar
• DiamondMAuroraSAmesMNaratriptan for intermittent prophylaxis for menstrually associated migraine: an analysis of migraine-free days [abstract]Headache2003405489
   Google Scholar
• EdelsonRNMenstrual migraine and other hormonal aspects of migraineHeadache19852537693908402
   PubMed Web of Science ®Google Scholar
• FacchinettiFBonellieGKangasniemiPThe efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study GroupObstet Gynecol199586911167501338
   PubMed Web of Science ®Google Scholar
• GranellaFSancesGAllaisGCharacteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centresCephalagia20042470716
   PubMed Web of Science ®Google Scholar
• [HCC] Headache Classification Committee of the International Headache SocietyClassification and diagnostic criteria for headache disorders, cranial neuralgias and facial painCephalagia19888S7196
   Google Scholar
• [HCS] Headache Classification Subcommittee of the International Headache SocietyThe international classification of headache disordersCephalagia2004242nd edSupp 11169
   Google Scholar
• HuXHMarksonLELiptonRBBurden of migraine in the United States: disability and economic costsArch Intern Med19991598131810219926
   PubMed Web of Science ®Google Scholar
• JohannesCBLinetMSStewartWFRelationship of headache to phase of the menstrual cycle among young women: a daily diary studyNeurology1995451076827783866
   PubMed Web of Science ®Google Scholar
• KarageorgiouCEHatzidakiGRobotisGThe role of naratriptan as a prophylaxis to the menstrual migraine: a pilot comparative to naproxen study [abstract]Cephalagia200121P2
   PubMedGoogle Scholar
• KingDSHerndonKCDiPiroJTHeadache disordersPharmacotherapy20056th edNew YorkMcGraw Hill110521
   Google Scholar
• LiptonRBDiamondSReedMMigraine diagnosis and treatment: results from the American migraine study IIHeadache200141638411554951
   PubMed Web of Science ®Google Scholar
• LiptonRBStewartWFMigraine in the United States: A review of epidemiology and health care useNeurol199343S3610
   Google Scholar
• LoderESilbersteinSDAbu-ShakraSEfficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled studyHeadache2004441203014756849
   PubMed Web of Science ®Google Scholar
• MacGregorEAMenstruation, sex hormones, and migraineNeurol Clin199715125419058401
   PubMed Web of Science ®Google Scholar
• MacGregorEAKeywoodCFrovatriptan is effective in menstrually associated migraine [abstract]Cephalagia200020345
   Google Scholar
• MannixLBrandesJShackelfordSNaratriptan for intermittent prophylaxis for menstrually associated migraine: a review of efficacy and tolerability [abstract]Headache20034058710940098
   PubMed Web of Science ®Google Scholar
• MarksDRRapoportAMDiagnosis of migraineSemin Neurol19971730369474709
   PubMed Web of Science ®Google Scholar
• MassiouHIs menstrually associated migraine difficult to treat?Cephalagia199919Suppl 241318
   PubMed Web of Science ®Google Scholar
• MullenersWMAuroraSKChronicleEPSelf-reported photophobic symptoms in migraineurs and controls are reliable and predict diagnostic category accuratelyHeadache20014131911168601
   PubMed Web of Science ®Google Scholar
• NettRMannixLKLandySA randomized, double-blind, placebo-controlled, parallel-group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually associated migraine [abstract]Neurology200360Suppl 1A95
   Google Scholar
• NewmanLMannixLKLandySNaratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled studyHeadache2001412485611264684
   PubMed Web of Science ®Google Scholar
• ParsonsAARavalPSmithSEffects of the novel high-affinity 5-HT1B/1D-receptor ligand frovatriptan in human isolated basilar and coronary arteriesJ Cardiovasc Pharmacol19983222049700983
   PubMed Web of Science ®Google Scholar
• RussellMBRasmussenBKFengerKMigraine without aura and migraine with aura are distinct clinical entities: a study of four hundred and eighty-four male and female migraineurs from the general populationCephalagia19961623945
   PubMed Web of Science ®Google Scholar
• SilbersteinSDMerriamGREstrogens, progestins, and headacheNeurology199141786932046918
   PubMed Web of Science ®Google Scholar
• SilbersteinSDElkindAHSchreiberCA randomized trial of frovatriptan for the intermittent prevention of menstrual migraineNeurology200463261915277618
   PubMed Web of Science ®Google Scholar
• SingerRSchimJFrovatriptan for prophylaxis of menstrually associated migraine: efficacy and tolerability in patients using oral contraceptives compared with nonusers [abstract]Headache200343587
   Google Scholar
• SmithTRNettRFrovatriptan is well tolerated during repeated use for intermittent prevention of menstrually associated migraine [abstract]Headache200343586
   Google Scholar
• StewartMNapierCMKatugampolaSDThe binding affinity and functional activity of eletriptan and other 5-HT 1B/1D agonists at the human recombinant 5-HT1B and 5-HT1D receptors [abstract]Br J Pharmacol199912793
   Web of Science ®Google Scholar
• StewartWFShechterARasmussenBKMigraine prevalence. A review of population-based studiesNeurology1994446 Suppl 4S17238008222
   PubMed Web of Science ®Google Scholar
• StewartWFLiptonRBCheeEMenstrual cycle and headache in a population sample of migraineursNeurology20005515172311094107
   PubMed Web of Science ®Google Scholar
• TepperSJRapoportAMSheftellFDMechanisms of action of the 5-HT1B/1D receptor agonistsArch Neurol2002591084812117355
   PubMed Web of Science ®Google Scholar
• TepperSFreitagFIntermittent use of frovatriptan for prevention of menstrually associated migraine is effective and does not cause rebound migraine in the postdosing period [abstract]Headache200343585
   Google Scholar
• TuckmanMHeeAEmeribeUOral zolmitriptan 2.5mg demonstrates high efficacy and good tolerability in the prophylactic treatment of menstrual migraine headaches [abstract]Headache200545771
   Web of Science ®Google Scholar